<DOC>
	<DOCNO>NCT00554333</DOCNO>
	<brief_summary>Primary objective : * Immunogenicity To demonstrate influenza vaccine administer intradermal route least immunogenic adjuvanted influenza vaccine administer intramuscular route dosage term HA antibody titres Secondary objective - Immunogenicity - To describe immune response 21 day vaccination influenza vaccine administer ID route versus adjuvanted influenza vaccine administer IM route.. - To describe compliance vaccine administer European Medicine Agency ( EMEA ) Note Guidance immunogenicity criterion , specific elderly subject - Safety - To describe safety profile vaccination group - Acceptability - To describe pain injection site - To describe comfort injection</brief_summary>
	<brief_title>Comparative Study Immunogenicity Safety Flu-ID Vaccine Versus Flu-IM Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 65 year old day inclusion Febrile illness ( oral temperature ≥37.5°C ) day inclusion Thrombocytopenia bleed disorder contraindicate intramuscular vaccination Unstable chronic illness Congenital acquire immunodeficiency , Any blood bloodderived product past 3 month Current abuse alcohol drug addiction Any vaccination past 4 week plan 4 week follow study vaccination Any vaccination influenza past 6 month Subjects previously receive vaccination influenza intradermal route</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>